Sortilin has been associated with the progression and aggressiveness of several malignancies, including liver cancer [7,8], pancreatic cancer [9], breast cancer [10,11], metastatic melanoma [12], and colorectal cancer [13]. This evidence concerns the gene SORT1 and familial pancreatic carcinoma.